Shawn French, DO
Pulmonary Disease · Twin Falls, IDNPI 1124238449
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,600 of the $25,910 with a category attached, or 83.4%. GSK accounts for 90.7% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2020 at $14,987 and has fallen 96.9% since, to $463 in 2025. Among pulmonary disease clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 243 payments — averaging $106.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$24K
- AstraZeneca$1K
- Actelion Pharmaceuticals US, Inc.$314
- Sanofi-aventis U.S. LLC$197
- Boehringer Ingelheim$157
- Grifols USA, LLC$153
- plus $583 from 17 others
What the payments were for
- Speaking & faculty fees$21,60083%
- Travel & lodging$3501%
- Food & beverage$3,68114%
- Education$2791%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 134 | $23,500 |
| AstraZeneca | 42 | $1,007 |
| Actelion Pharmaceuticals US, Inc. | 13 | $314 |
| Sanofi-aventis U.S. LLC | 2 | $197 |
| Boehringer Ingelheim | 10 | $157 |
| Grifols USA, LLC | 8 | $153 |
| United Therapeutics Corporation | 6 | $113 |
| Amgen | 4 | $82 |
| Bayer | 3 | $50 |
| Genentech USA, Inc. | 3 | $45 |
| Sunovion Pharmaceuticals Inc. | 3 | $42 |
| Sanofi | 2 | $38 |
| Mylan Specialty L.p. | 2 | $29 |
| Insmed, Inc. | 2 | $27 |
| Pulmonx Corporation | 1 | $27 |
| Advanced Respiratory, Inc | 1 | $21 |
| Vifor Pharma, Inc. | 1 | $18 |
| Medical Graphics Corporation | 1 | $17 |
| Viatris Specialty LLC | 1 | $16 |
| Novartis | 1 | $15 |
| Gilead | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$21,962
- BREZTRI$244
- TEZSPIRE$221
- FASENRA$119
- NUCALA$105
How this compares
$25,910 in reported general payments places this provider in the 90th percentile of 57 pulmonary disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 379 | $289,659 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 74 | $55,375 |
| Spiriva RespimatTiotropium Bromide | 76 | $53,128 |
| Breo ElliptaFluticasone/Vilanterol | 104 | $51,358 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 90 | $42,742 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 70 | $36,467 |
| SymbicortBudesonide/Formoterol Fumarate | 61 | $19,050 |
| Incruse ElliptaUmeclidinium Bromide | 43 | $17,592 |
| Advair HfaFluticasone Propion/Salmeterol | 29 | $11,487 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 355 | $11,377 |
| Spiriva HandihalerTiotropium Bromide | 17 | $10,312 |
| EliquisApixaban | 13 | $9,136 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 47 | $6,579 |
| BreynaBudesonide/Formoterol Fumarate | 37 | $6,073 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 44 | $5,500 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $23,500 | $395,075596 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $157 | $95,870166 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,007 | $79,298147 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 57 pulmonary disease providers in Idaho.
Other pulmonary disease in Twin Falls
- Gregory BallTwin Falls$6K
- Gary DrizinTwin Falls$3K
- Joseph EzerTwin Falls$0
- Todd HoopmanCoeur D Alene$76K
- Allen SalemIdaho Falls$44K
- Mark RasmusBoise$44K
- Karen MillerMeridian$12K
- Wesley PidcockNampa$12K
- Norman EastBoise$11K
- Jordan CormierIdaho Falls$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.